The annual emergence of seasonal influenza remains one of the most persistent challenges in global public health. Every year, scientists and health officials engage in a complex effort to predict which strains of the virus will circulate, allowing for the development of vaccines that can mitigate the impact of the disease. However, the mechanisms that dictate why one specific variant of the flu rises to dominance while others fade away have long remained partially obscured. A groundbreaking new study has now shed light on this evolutionary puzzle, revealing that the key to predicting viral success lies not in the average immunity of a population, but in the intricate, person-to-person variations in antibody responses.
The research, published as a Reviewed Preprint in the journal eLife, introduces a sophisticated high-throughput sequencing-based assay designed to quantify antibody immunity against circulating H3N2 influenza strains. By analyzing samples from both children and adults, the study provides a detailed map of how individual immune histories create a "patchwork" of vulnerability that the virus exploits to evolve. The editors at eLife have characterized the work as an important advancement in the field of population-level immunity, noting that the strength of the evidence presented is compelling. The findings are expected to have a significant impact on the work of immunologists, virologists, vaccine developers, and mathematical modelers who track the trajectory of infectious diseases.
At the heart of the influenza virus’s success is its ability to undergo "antigenic drift." This process involves the accumulation of mutations, particularly in the hemagglutinin (HA) protein, which is the primary target for the human immune system. Hemagglutinin acts like a key that allows the virus to latch onto and enter human cells; antibodies work by "clogging" this key so it can no longer function. However, as the virus mutates, the shape of the HA protein changes, eventually rendering existing antibodies ineffective. This constant evolution is why individuals can be reinfected with the flu multiple times throughout their lives and why the composition of flu vaccines must be reviewed and updated twice a year.
The human immune response to these changes is not a blank slate. Instead, it is deeply influenced by an individual’s "immunological memory"—the record of every flu infection and vaccination they have ever experienced. "Differences in infection and vaccination histories within a group of people mean that population immunity to a specific variant of the flu is highly varied," explained co-lead author Caroline Kikawa, an MD/PhD student at the University of Washington and the Fred Hutch Cancer Center. Kikawa noted that while this variety was known to exist, understanding its specific impact on the evolutionary success of new strains has been a major hurdle for the scientific community.
The primary obstacle has been technological. Conventional methods used to quantify antibody levels, such as the hemagglutination inhibition assay, are labor-intensive and relatively slow. These traditional tests can typically only assess a small number of samples against a limited selection of viral strains at one time, making it nearly impossible to get a comprehensive view of how an entire population might respond to a diverse array of emerging variants.
To overcome this, Kikawa and co-lead author Andrea Loes, a Staff Scientist and Lab Manager at the Fred Hutch Cancer Center, worked with senior author Jesse Bloom to develop a high-throughput neutralization assay. This new method allows researchers to process vast amounts of data simultaneously, providing a high-resolution look at the battle between antibodies and viruses.
In the study, the research team engineered viruses to express 78 distinct hemagglutinin proteins, representing the diversity of H3N2 flu viruses circulating in 2023, as well as recent vaccine strains. Each of these 78 variants was tagged with a unique genetic "barcode." By mixing these barcoded viruses with human sera—the antibody-rich component of blood—and using Illumina sequencing, the researchers could measure exactly how well each individual’s antibodies neutralized every one of the 78 variants.
The scale of the data generated was unprecedented. The team analyzed 150 serum samples collected in 2023 from a diverse group of children and adults in the United States. In total, they produced over 11,000 individual titer measurements. This massive dataset created a detailed "snapshot" of the state of human immunity at the threshold of the 2023–2024 flu season.
The results revealed a staggering level of variation in how individuals respond to the flu. The researchers found that immunity is highly personalized; two people of the same age living in the same city might have radically different levels of protection against the same strain of flu based on which specific viruses they caught years earlier. The study found that some children possessed antibodies that could strongly neutralize almost every strain tested. In contrast, other children had much weaker responses across the board. While adults generally exhibited more consistent levels of immunity, they still showed significant individual variation.
One of the most striking observations was that the highest rates of neutralization were found in a subset of children. The researchers suggested two possible reasons for this. First, it aligns with the concept that immune responses are often most robust against strains encountered during the first decades of life—a phenomenon sometimes referred to as "original antigenic sin" or primary exposure. Second, children are generally more susceptible to frequent respiratory infections, meaning they may have had more recent "immunological boosting" from natural infections compared to adults.
To determine how this individual variation actually influences the path of viral evolution, the researchers utilized a statistical model known as multinomial logistic regression. They compared their 11,000 titer measurements with the actual growth rates of different H3N2 strains observed during the 2023 flu season. The goal was to see if the immunity profile of the 150 individuals could predict which viral strains would successfully spread through the wider population.
The analysis revealed a clear and significant correlation: the flu strains that spread most successfully were those that managed to "escape" neutralization in a larger fraction of the individual serum samples. Crucially, the researchers found that a strain’s success was best predicted by the percentage of the population that fell below a specific threshold of immunity. If a high percentage of individuals had weak or no protection against a specific variant, that variant was much more likely to surge in frequency.
This finding carries profound implications for how we monitor the flu. Currently, many virus surveillance systems rely on "pooled" serum samples—where blood from many individuals is mixed together—to estimate the average immunity of a population. However, the researchers found that the relationship between immunity and viral growth held true only when looking at individual samples. When the data was averaged out or "pooled," the nuances of the population’s vulnerability were lost, and the predictive power of the data vanished.
"Our findings show that individual-level immune variation, not just average immunity across the population, is a key factor in determining which flu strains are most successful," said Andrea Loes. This suggests that current surveillance methods might be overlooking the very "pockets" of vulnerability that allow new flu variants to gain a foothold and eventually dominate a season.
Despite the depth of the data, the authors were careful to acknowledge the limitations of their study. The serum samples were obtained from a relatively narrow geographic range: children’s samples came primarily from a hospital in Seattle, while adult samples were sourced from vaccinated groups in Philadelphia and Australia. Because flu circulation patterns and vaccination rates can vary significantly by region, the researchers noted that their dataset might not fully represent the global landscape of immunity.
Nevertheless, the study represents a major leap forward in the field of genomic surveillance. Jesse Bloom, a Professor at the Fred Hutch Cancer Center and an HHMI Investigator, emphasized the broader potential of this framework. "This is nevertheless one of the largest datasets linking human antibody immunity to the success of flu virus strains in a population," Bloom stated. "It provides a framework for understanding how diverse immune histories can affect viral evolution. These methods could complement existing surveillance systems and support vaccine composition decisions by providing more detailed insights into population immunity."
As the world continues to grapple with the threat of seasonal epidemics and the ever-present risk of a flu pandemic, the ability to decode the "immune landscape" of the population becomes increasingly vital. By moving away from simple averages and embracing the complexity of individual immune diversity, scientists may soon be able to predict the next move of the influenza virus with greater precision than ever before. This high-throughput approach offers a new lens through which to view the evolution of pathogens, potentially leading to more effective vaccines and a more proactive stance against one of humanity’s most resilient viral foes.
